Shares of Hims & Hers Health ($HIMS) rallied on Tuesday after management said it’s in discussions with Novo Nordisk ($NVO) to ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Hims & Hers Health’s third quarter results prompted a positive market reaction as the company delivered strong revenue growth ...

Less than six months after ending a short-lived partnership, US telehealth firm Hims & Hers (Nasdaq: HIMS) and Danish ...

Global populations are aging, a reality that is leading to increased demand for healthcare services, chronic disease ...

Hims & Hers posted record revenue this quarter. It is still selling patented weight loss drugs on its platform and is now getting sued by the pharmaceutical companies. Investors would do best to avoid ...

Hims & Hers Health (NYSE: HIMS) is a telehealth company that offers personalized solutions for its customers. And demand has been robust, with subscriptions for its products rising significantly in ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

In a surprising turn of events, Hims and Hers Health has reported a third-quarter profit that fell short of Wall Street expectations. The company, which has gained popularity for its telehealth ...

HIMZ offers 2x leveraged exposure to HIMS, ideal for high-risk, short-term traders seeking amplified volatility, not long-term investors. Recent HIMS volatility, including the Novo Nordisk partnership ...

Hims & Hers Health, Inc. HIMS is scheduled to report third-quarter 2025 results on Nov. 3, after the closing bell. In the ...